Nutriband Inc. (NTRB)
|Net Income (ttm)||-1.63M|
|Trading Day||January 15|
|Day's Range||12.50 - 12.50|
|52-Week Range||6.02 - 19.74|
There are no news available yet.
Nutriband develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain. Its product line consists of an energy patch line; a weight management patch line; a multivitamin patch line; a children's multivitamin patch line; an amino acid patch line; an anti-wrinkle patch line; an insect repellant patch line; a detox patch line; a PMS patc... [Read more...]
|Stock Exchange |
|Ticker Symbol |
In 2019, Nutriband's revenue was $370,647, an increase of 51.11% compared to the previous year's $245,285. Losses were -$2.72 million, -18.30% less than in 2018.
The average 12-month stock price forecast for Nutriband is 24.00, which is an increase of 92.00% from the latest price.